Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - A double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 10, 2011, Pages 1123-1132

  Guglielmetti, S ^a   Mora, D ^a   Gschwender, M ^b   Popp, K ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Department of the Nutritional Study ^*

Author keywords

[No Author keywords available]

Indexed keywords

BIFIDOBACTERIUM BIFIDUM MIMBB75; BISACODYL; LOPERAMIDE; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BLOATING; CONTROLLED STUDY; DEFECATION URGENCY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; BIFIDOBACTERIUM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954738618     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04633.x     Document Type: Article

References (29)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Madden JA, Hunter JO,. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002; 88 (Suppl 1): S67-72. (Pubitemid 35251945)
3. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR,. Clinical trial: the effects of a trans-galactosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-18.
4. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS,. The utility of probiotics in the treatmet of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-49.
5. Pimental M, Chow EJ, Lin HC,. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-6.
6. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH,. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowl syndrome. Aliment Pharmacol Ther 2008; 28: 994-1002.
7. Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkertin, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-22. (Pubitemid 40040078)
8. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33. (Pubitemid 47031125)
9. Mättö J, Maunuksela L, Kajander K, et al., Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213-22. (Pubitemid 40170291)
10. Alvares-Olmos MI, Oberhelman RA,. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001; 32: 1567-76. (Pubitemid 32458724)
11. Salminen S, Isolauri E, Salminen E,. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996; 70: 347-58. (Pubitemid 26355508)
12. Fanigliulo L, Comparato G, Aragona G, et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77: 85-9.
13. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51. (Pubitemid 40585355)
14. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R,. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-94. (Pubitemid 41248105)
15. Guglielmetti S, Tamagnini I, Mora D, et al. Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells. Appl Environ Microbiol 2008; 74: 4695-702.
16. Guglielmetti S, Tamagnini I, Minuzzo M, et al. Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines. Curr Microbiol 2009; 59: 167-72.
17. Whorwell PJ, Altringer L, Morel J, et al,. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90. (Pubitemid 43980633)
18. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2008; 29: 97-103.
19. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-86. (Pubitemid 47063138)
20. Marteau P,. Probiotics in functional intestinal disorders and IBS: proof of action and dissecting the multiple mechanisms. Gut 2010; 59: 285-6.
21. Bausserman M, Michail S,. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147: 197-201. (Pubitemid 41207833)
22. Niv E, Naftali T, Hallak R, Vaisman N,. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndromeâa double blind, placebo-controlled, randomized study. Clin Nut 2005; 24: 925-31. (Pubitemid 41782449)
23. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-96. (Pubitemid 41400717)
24. Sen S, Mullan MM, Parker TJ, et al,. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-20. (Pubitemid 35305475)
25. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-92.
26. Si JM, Yu YC, Fan YJ, Chen SJ,. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802-5.
27. Pimental M, Chow EJ, Lin HC,. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9. (Pubitemid 36232393)
28. Dear KLE, Elia M, Hunter JO,. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005; 50: 758-66. (Pubitemid 40558474)
29. Quigley EM,. Probiotics in irritable bowel syndrome: an immunomodulatory strategy? J Am Coll Nutr 2007; 26: 684S-90S.